Autoverification

11/18/2014

Matthew D. Krasowski, MD, PhD
University of Iowa Hospitals and Clinics (UIHC)
Director of Clinical Laboratories
mkrasows@healthcare.uiowa.edu
Disclosures

• In the past 12 months, I have not had a significant financial interest or other relationship with the manufacturers of the products or providers of the services that will be discussed in my presentation.
Objectives

• **Learning Outcome 1:**
  Participants will be able to recognize the benefits and challenges of auto-verification of clinical laboratory results.

• **Learning Outcome 2:**
  Participants will be able to identify the parameters in clinical laboratory testing that are amenable to auto-verification.

• **Learning Outcome 3:**
  Participants will be able to describe how to design, validate, and implement auto-verification rules using CLSI guidelines as a guide.
Growing pressures on clinical laboratories

• “Do more with less!”

• Multiple factors are placing strain on clinical laboratories
  – Aging workforce
  – Insufficient numbers of new employees entering laboratory medicine
  – Continual pressure to reduce labor and supply costs
  – Declining revenue streams
Opportunities to increase efficiency

- Automated instruments
- *Auto-verification*
- Removing redundant practices
- Tackle mis-utilization of laboratory testing

- In general, optimize manual efforts of laboratory staff
Common time-consuming practices

- Manual verification of results
- Calls to clinical services
  - Critical values
  - Suboptimal specimens
- Manual re-run of specimens
- Dilution of specimens to obtain exact analyte concentration if not clinically useful
- Segregation of specimens into stat vs. routine
Critical values
Critical results (values)

- Joint Commission: “a pathophysiologic state at such variance with normal as to be life threatening if an action is not taken quickly and for which an effective action is possible”

- Critical result policies vary based on institution with no clear national guidelines
  - Influenced by population being tested and on-site test menu
Two common practices

1. Analysis repeated for specimens with critical values

2. Manual verification of all critical results—not auto-verified
Critical results must be re-analyzed

• Get the data!
  – How often does repeat analysis change results?

• If data does not support - why delay reporting of the most time-sensitive results?

• Just because result is physiologically abnormal doesn’t mean analysis is suspect
  – Distinguish from potentially “absurd” values (e.g., contaminated specimens)
  – Many critical results are well within analytical measuring range (AMR)
    • E.g., Serum K$^+$ of 2.4 or 7.5 mEq/L is generally well within AMR of most assays
“Critical results cannot be auto-verified”

• Common misconception – many believe that manual result release and notification of clinical service need to be coupled

• Auto-verification is acceptable by regulations and in fact can lead to better clinical care

• Still need to notify clinical service and document appropriately
Auto-verification
Research Article

Autoverification in a core clinical chemistry laboratory at an academic medical center

Matthew D. Krasowski¹, Scott R. Davis¹, Denny Drees¹, Cory Morris¹, Jeff Kulhavy¹, Cheri Crone¹, Tami Bebber¹, Iwa Clark¹, David L. Nelson¹, Sharon Teul¹, Dena Voss¹, Dean Aman², Julie Fahnle², John L. Blau¹,³

¹Departments of Pathology, ²Hospital Computing Information Systems, University of Iowa Hospitals and Clinics, Iowa City, IA, USA ³Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA

E-mail: *Dr. Matthew D. Krasowski - mkrasows@healthcare.uiowa.edu
*Corresponding author

Received: 17 December 2013        Accepted: 13 February 2014        Published: 28 March 14
University of Iowa Hospitals and Clinics (UIHC)

- 735 bed medical center located in Iowa City, IA
- Multi-specialty outpatient facility in nearby Coralville, IA
- Level 1 trauma center
- Referral center for many specialties
UIHC clinical laboratories

- Approximately 4 million billable tests per year

- LIS – Cerner Classic

- Several main laboratory sections
  - Core laboratory with chemistry, hematology, and flow cytometry
  - Microbiology and molecular pathology
  - DeGowin Blood Center
  - Anatomic pathology
Auto-verification

- Verification of results without manual human action
  - Reduces time spent manually reviewing results

- Use pre-defined rules (indices, reference ranges, critical values) to govern release of results
  - Rules can define whether to auto-release results or hold for human intervention
  - Standardize result review (need to consider screen fatigue from staff manually reviewing hundreds or thousands of results per day)
Parameters often included in auto-verification rules

- Analyte reference (normal) ranges
- Instrument flags (short sample, possible bubble or clot, etc.)
- Indices (hemolysis, lipemia, icterus)
- Delta checks
- Calculations
- Conditions for re-analysis
  - Repeat measurement
  - Dilutions
  - Assays that occasionally give erroneous ‘fliers’
Example autoverification scheme

Are there any instrument error flags?

Are interference indices (hemolysis, icterus, lipemia) exceeded?

Check rules for questionable specimen

Are manual review limits triggered?

Does value exceed AMR?

Is value below AMR?

Are delta checks required and, if so, are they passed?

Example autoverification scheme (cont.)

Is result a critical value?

Are any rules for analytic consistency violated?

Is any repeat testing needed?

Is any reflex testing generated by result?

Is notification of medical director or pathology resident required?

Follow rules to format results and, if applicable, generate interpretive comment

Delta checks

• Comparing current patient result to previous results on same patient
  – Manual verification required if delta check limits exceeded
  – May be only way to detect mis-identified specimens (e.g., wrong patient label on a tube)

• However, if not set up well, can dramatically reduce rate of auto-verification
  – Can be especially tricky if testing a wide variety of patients (e.g., outpatients and ICUs)
Reference Change Value (RCV)

- May be used to determine delta check limits using analytical and biological variation

\[
RCV = 2^{0.5} \times Z \times (CV_A^2 + CV_I^2)^{0.5}
\]

- Z score = 1.96 at 95% probability and 2.58 at 99% probability
- \(CV_A\) = analytical variation
- \(CV_I\) = intra-individual variation (see http://www.westgard.com/biodatabase1.htm or find in published literature)
Example RCV calculation

- Albumin has a $CV_A$ of 2.0% at 3 g/dL
- $CV_I$ is 3.2% (Westgard website)

\[
RCV \text{ at } 99\% = 1.414 \times 2.58 \times (2^2 + 3.2^2)^{0.5} = 13.8\%
\]

- If the lab is interested in large variations in albumin ($P < 0.01$), a delta check limit of 13.8% or greater change in serial results could be set. This is equivalent to absolute difference of $\sim0.4$ g/dL at 3 g/dL levels.
Index of Individuality

- Indicates which analytes are more likely to fluctuate within an individual
- Ratio of intra-individual variation ($CV_I$) and between-individual variation ($CV_G$)

$$=(CV_I/CV_G)$$

Ratio $< 0.6$ indicates analyte values are tightly regulated within an individual although they may vary between individuals

## Index of Individuality

<table>
<thead>
<tr>
<th>Analyte (units)</th>
<th>Index of individuality</th>
<th>Method CV, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alanine aminotransferase (U/L)</td>
<td>0.47</td>
<td>3.2</td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td>0.31</td>
<td>3.4</td>
</tr>
<tr>
<td>Alkaline phosphatase (U/L)</td>
<td>0.13</td>
<td>6.5</td>
</tr>
<tr>
<td>Apolipoprotein A (g/L)</td>
<td>0.39</td>
<td>4.8</td>
</tr>
<tr>
<td>Apolipoprotein B (g/L)</td>
<td>0.34</td>
<td>2.7</td>
</tr>
<tr>
<td>Aspartate aminotransferase (U/L)</td>
<td>0.52</td>
<td>3.4</td>
</tr>
<tr>
<td>β-Carotene (μmol/L)</td>
<td>0.36</td>
<td>7.4</td>
</tr>
<tr>
<td>β-Cryptoxanthin (μmol/L)</td>
<td>0.35</td>
<td>7.7</td>
</tr>
<tr>
<td>Bicarbonate (mmol/L)</td>
<td>0.83</td>
<td>2.4</td>
</tr>
<tr>
<td>Bilirubin, total (μmol/L)</td>
<td>0.56</td>
<td>3.0</td>
</tr>
<tr>
<td>C peptide (nmol/L)</td>
<td>0.43</td>
<td>7.2</td>
</tr>
<tr>
<td>Calcium, ionized (mmol/L)</td>
<td>0.67</td>
<td>1.4</td>
</tr>
<tr>
<td>Calcium, total (mmol/L)</td>
<td>0.70</td>
<td>2.2</td>
</tr>
<tr>
<td>Chloride (mmol/L)</td>
<td>0.61</td>
<td>1.0</td>
</tr>
<tr>
<td>Cholesterol, total (mmol/L)</td>
<td>0.37</td>
<td>2.3</td>
</tr>
<tr>
<td>Creatinine (μmol/L)</td>
<td>0.36</td>
<td>1.0</td>
</tr>
<tr>
<td>Creatinine, urine (mmol/L)</td>
<td>0.70</td>
<td>2.2</td>
</tr>
</tbody>
</table>

Analytes with low intra-individual variability often used for delta checks

- Alkaline phosphatase
- Bilirubin
- Creatinine
- MCV
Limitations of delta checks

- May not have access to prior results (e.g., transferred patients)
- Limited aid in outpatients with infrequently performed labs
- Patients may show dramatic changes in analytes that are part of disease process or due to treatment (e.g., dialysis, transfusions, chemotherapy)
Define potentially absurd values

- Examples depend on clinical population

- Very low plasma glucose (e.g., < 10 mg/dL)
  - May have different limits for infants vs. adults

- $K^+ > 11$ mEq/L often artefactual

- [Direct bili] $>>$ [total bili]

- Creatinine very abnormal with normal BUN

- [Albumin] $>$ [Total protein]

- AST and ALT very discordant
Auto-verification rules packages

• Some vendors offer pre-set rules packages
  – Can provide starting point for labs new to auto-verification

• Wise to start simply and then build from there

• Takes time to build comfort level and expertise with auto-verification
Validation plan for auto-verification

- Pre-testing
- Simulated patient testing
- Testing using clinical specimens
- Approval of documentation
- Implementation and maintenance of rules

- *CLSI Autoverification of Clinical Laboratory Test Results; Approved Guideline (AUTO10-A)*
Validation challenges

• Generally wise to have “test” environment

• Cannot test every scenario

• But make best effort to test every:
  – Test code
  – Upper and lower limits (including “boundaries”)
  – Rules individually and in combination
  – Result integrity to LIS
  – Result reporting to HIS
Testing Clinical Specimens

• Pays to collect “unusual” specimens

• Especially valuable to save specimens with:
  – Abnormal results
  – Interferences (hemolyzed, icteric, and lipemic)
  – Results less than analytical measurement range (AMR), if available; otherwise, may need to dilute
  – Values exceeding AMR (e.g., test auto-dilution protocols)
Regulations/guidelines – CAP

• CAP GEN.43850 Autoverification approval
  – There is a policy signed by the laboratory director approving use of auto-verification procedures

• CLSI Autoverification of Clinical Laboratory Test Results; Approved Guideline (AUTO10-A)
  – Qualified Laboratory Director must establish policies and procedure for allowing auto-verification
Practical challenges

• Determine scope of project
  – Identify key staff
  – Will auto-verification be done in middleware or LIS or both?
  – Allocate time for rule writing and testing

• Benefits of auto-verification unfold over time
  – May save 5-20 secs of manual time hundreds of times per day

• Coordinate with LIS operation
Auto-verification in middleware or LIS?

• Depends on instrumentation, informatics capability within clinical laboratory, and functionality of LIS

• Where are the informatics personnel resources?
  – Can resources be “home-grown”? 
Potential value of middleware

- May be more easily under control by clinical laboratory staff

- Technologists can quickly intervene (e.g., suspending auto-verification rules) if problem arises

- If using LIS for auto-verification, how much will this task compete with hospital computing services resources?
Maintenance of auto-verification

• Need ability to shut off autoverification if necessary

• Annual audits

• Strongly recommend robust backup system with downtime procedure
  – Using middleware, can sometimes maintain operations even with LIS entirely down for scheduled or unscheduled downtimes
Key goals to success

- Realize significant investment is needed, including nurturing of staff with informatics skills
- Good project management
- Robust validation
- Ownership by lab staff (may find some staff uncomfortable initially with change in practice)
UIHC experience

• Beginning in 2005, began putting significant investment into informatics
  – Team of 4 technologists within core laboratory developed and validated ~1,500 rules governing auto-verification of results
  – Some technologists moved to hospital informatics over time

• Moved to lithium heparin plasma separator tube for most chemistry tests
  – Avoid micro-clots
UIHC Core Chemistry

• Systematically evaluated a variety of practices
  – Critical look at all manual process by literature review and own studies
  – Repeating analysis of critical values
  – Defining potentially “absurd” values (e.g., plasma potassium of 15 mEq/L)
Actions taken

• Completely eliminated ability to request assays stat (everything routine – “one-piece flow”)

• Auto-verification of critical values

• Eliminated routine practice of repeating critical values except when past evidence showed this had value
Auto-verification at UIHC

• By 2010, over 99% of chemistry results were being auto-verified
  – This included nearly all critical values

• Performed rigorous variance review

• Common reasons for manual review include:
  – Specimen errors (bubbles, clot, short sample)
  – Need for manual dilution
  – Possible contamination flag
### Rates of autoverification

<table>
<thead>
<tr>
<th>Test(s)</th>
<th>Annual volume</th>
<th>Autoverification rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All chemistry tests</td>
<td>3,805,000</td>
<td>99.5%</td>
</tr>
<tr>
<td>Basic metabolic panel</td>
<td>114,140</td>
<td>99.6%</td>
</tr>
<tr>
<td>Electrolyte panel</td>
<td>1,320</td>
<td>98.6%</td>
</tr>
<tr>
<td>Lipid panel</td>
<td>31,000</td>
<td>98.6%</td>
</tr>
<tr>
<td>ACTH</td>
<td>830</td>
<td>98.6%</td>
</tr>
<tr>
<td>Bilirubin, direct</td>
<td>20,560</td>
<td>97.6%</td>
</tr>
<tr>
<td>Free light chains, serum</td>
<td>4,180</td>
<td>88.0%</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>2,450</td>
<td>94.0%</td>
</tr>
<tr>
<td>Hepatitis B surface antigen</td>
<td>12,050</td>
<td>97.8%</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>1,200</td>
<td>89.6%</td>
</tr>
<tr>
<td>SS-A</td>
<td>1,540</td>
<td>100%</td>
</tr>
<tr>
<td>Troponin T</td>
<td>17,910</td>
<td>99.2%</td>
</tr>
</tbody>
</table>

Common reasons preventing autoverification

<table>
<thead>
<tr>
<th>Test(s)</th>
<th>Most common reasons preventing autoverification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic metabolic panel</td>
<td>Contamination flag, specimen error*, delta check failure</td>
</tr>
<tr>
<td>Electrolyte panel</td>
<td>Contamination flag, specimen error*, delta check failure</td>
</tr>
<tr>
<td>Lipid panel</td>
<td>Specimen error*</td>
</tr>
<tr>
<td>ACTH</td>
<td>Specimen error*</td>
</tr>
<tr>
<td>Bilirubin, direct</td>
<td>Exceeded AMR – manual dilution</td>
</tr>
<tr>
<td>Free light chains, serum</td>
<td>Exceeded AMR – manual dilution</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>Exceeded AMR – manual dilution</td>
</tr>
<tr>
<td>Hepatitis B surface antigen</td>
<td>Repeat testing for positives and grayzones</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Exceeded AMR – manual dilution</td>
</tr>
<tr>
<td>Troponin T</td>
<td>Specimen error*</td>
</tr>
</tbody>
</table>

* Examples include bubble, clot, short specimen, etc.

Comments from core laboratory staff

“Autoverification saves time for the filing person. It eliminates mistakes by people when interpreting results.”

“Autoverification lessens the workload at the filing bench to allow me to perform other tasks required in the immediate area.”

“One person can run chemistry by themself, the others can help where needed.”
‘Push’ technology

• Printouts generated by LIS or Middleware provide clear instructions what to do
  – Critical values
  – Confirmatory testing
  – Manual dilutions
  – Situations to contact laboratory director or pathology resident
  – Can be especially helpful for rare scenarios by ‘scripting’ actions to take
Example print-out #1: notification to staff (either call center or main laboratory) to call critical value that has already been auto-verified
A CRITICAL $K^+$ result has been resulted for this patient. Call area and document in RIA.
Example print-out #2

• Less common scenario

• Total bilirubin very discrepant from icteric index

• Can be caused by monoclonal gammopathy, most often IgM (package insert data)
The BILT minus ICT is $> 4$. Possible interference of bilirubin measurement due to abnormal proteins. If repeated BILT is now within 4 of ICT, reorder BILT, and file BILT result. If repeated BILT is still $> 4$ of ICT, review results and check LIS to see if evidence of myeloma (SPE, SIFE).

If any evidence of myeloma, access cancelled BILT in LIS and add phrase 'Interference due to myeloma protein'. Present findings to Path resident and [Clinical Chemistry Director]."
Clinical implications

• In many cases, clinicians are seeing critical values before we even make the call (especially in ICU and emergency center)
  – Makes the phone notification much easier and is consistent with regulatory initiatives to speed reporting of critical values

• Very few complaints about turnaround time
  – TAT issue is almost always due to delay in sample getting to lab
  – Consistency in TAT is also important
Upfront investment pays off

• Much of the upfront work is rule writing and verification
  – This expertise can be transferred to other instrumentation

• Have been able to handle increased volumes without increase of staff in chemistry
Be prepared for downtimes

• Invest effort in preparing and practicing for downtimes
  – Backup servers
  – Developed clear downtime procedures and practiced
  – Incorporate into disaster drills
Summary

• Autoverification: 99.5%
  – Increased from 40% with LIS

• Volume Increased 18.5%
  – 2.7M in 2005 to 3.2M in 2010

• 32% Increase in Billables per Tech
  – $14.9 to $19.7 billable tests per hour

• Rules for Esoteric Patient Conditions
Acknowledgements

• UIHC Core Laboratory staff and management (especially Jeff Kulhavy, Sue Lewis, Scott Davis, Cheri Crone, Denny Drees, Cory Morris, Sharon Tuel, Dena Voss, Sue Zaleski)

• UIHC hospital informatics (especially Nick Dreyer, Rick Dyson, Kurt Wendel, Karmen Dillon, Lee Carmen, Dean Aman, Julie Fahnle)

• Ron Feld, PhD (emeritus)

• Jonathan Genzen (University of Utah/ARUP Laboratories)